With the development of more specific anti-cancer drugs, we decided to investigate the potential of the Polo-like kinase 1 (PLK1) inhibitor BI 2536 [3], [4] as a potential drug to eliminate proliferating cells from in vitro cultures containing terminally differentiated cardiomyocytes. Here, PLK1 is linked to cancer.